Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications

被引:40
|
作者
Chhabra, Gagan [1 ]
Singh, Chandra K. [1 ]
Ndiaye, Mary Ann [1 ]
Fedorowicz, Samantha [1 ]
Molot, Arielle [1 ]
Ahmad, Nihal [1 ,2 ]
机构
[1] Univ Wisconsin, Dept Dermatol, Madison, WI USA
[2] William S Middleton VA Med Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
Prostate cancer; Chemoprevention; Natural agents; Clinical trials; GREEN-TEA-CATECHINS; BASE-LINE CHARACTERISTICS; PLACEBO-CONTROLLED TRIAL; VITAMIN-E; SELENIUM SUPPLEMENTATION; PREVENTION TRIAL; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA; NUTRITIONAL PREVENTION; DOUBLE-BLIND;
D O I
10.1016/j.canlet.2018.02.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) is the most common non-skin cancer and the second leading cause of cancer related deaths in American men. Due to its long latency period, PCa is considered as an ideal cancer type for chemopreventive interventions. Chemopreventive agents include various natural or synthetic agents that prevent or delay cancer development, progression and/or recurrence. Pre-clinical studies suggest that many natural products and dietary agents have chemopreventive properties. However, a limited number of these agents have been tested in clinical trials, with varying success. In this review, we have discussed the available clinical studies regarding the efficacy of natural chemopreventive agents against PCa, including tea polyphenols, selenium, soy proteins, vitamins and resveratrol. We have also provided a discussion on the clinical challenges and opportunities for the potential use of chemopreventive agents against PCa. Based on available literature, it appears that the variable outcomes of the chemopreventive clinical studies necessitate a need for additional studies with more rigorous designs and methodical interpretations in order to measure the potential of the natural agents against PCa. Published by Elsevier B.V.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 50 条
  • [31] Prostate Cancer Screening-The Evidence, the Recommendations, and the Clinical Implications
    Chou, Roger
    LeFevre, Michael L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (24): : 2721 - 2722
  • [32] Cancer Chemoprevention by Pomegranate: Laboratory and Clinical Evidence
    Adhami, Vaqar Mustafa
    Khan, Naghma
    Mukhtar, Hasan
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2009, 61 (06): : 811 - 815
  • [33] Practical aspects of clinical trials on chemoprevention of prostate cancer
    van der Meijden, APM
    EUROPEAN UROLOGY, 1999, 35 (5-6) : 515 - 518
  • [34] Statistical considerations of chemoprevention clinical trials in prostate cancer
    Sylvester, R
    Collette, L
    EUROPEAN UROLOGY, 1999, 35 (5-6) : 519 - 522
  • [35] Inhibition of lipoxygenase activity - Implications for the treatment and chemoprevention of prostate cancer
    Nelson, Mark A.
    CANCER BIOLOGY & THERAPY, 2007, 6 (02) : 237 - 237
  • [36] Contemporary Strategies for Clinical Chemoprevention of Localized Prostate Cancer
    Kumar, Nagi B.
    CANCER CONTROL, 2024, 31
  • [37] DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications
    Muletier, Romane
    Bourgne, Celine
    Guy, Laurent
    Douge, Aurore
    CANCER MEDICINE, 2025, 14 (01):
  • [38] Chemoprevention of prostate cancer
    Klein, EA
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 54 (01) : 1 - 10
  • [39] Chemoprevention of Prostate Cancer
    Stephenson, Andrew J.
    Abouassaly, Robert
    Klein, Eric A.
    UROLOGIC CLINICS OF NORTH AMERICA, 2010, 37 (01) : 11 - +
  • [40] Chemoprevention in prostate cancer
    不详
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (08) : 1325 - 1325